Anti-tuberculosis drug resistance in strains of Mycobacterium tuberculosis isolated from patients in a tertiary hospital in Bahia

Brazilian Journal of Infectious Diseases

Volumn 11, Issue 3, 2007, Pages 331-338

  Matos, Eliana Dias ^a,c,d   Lemos, Antônio Carlos Moreira ^a,b   Bittencourt, Carolina ^a   Mesquita, Cristiane Leite ^a  

^a Octavio Mangabeira Hospital   (Brazil)

^b FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^c ESCOLA BAHIANA DE MEDICINA E SAÚDE PÚBLICA   (Brazil)

^d HEOM   (Brazil)

Author keywords

Bahia Brazil; Hospitals; Multiresistance; Mycobacterium tuberculosis; Resistance; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGE; AGED; ALCOHOLISM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; BRAZIL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENDER; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PREVALENCE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; TUBERCULOSIS;

EID: 35448938897     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1413-86702007000300007     Document Type: Article

References (34)

1. Dye C., Scheele S., Dolin P., et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999;282(7):677-86.
2. Encerramento dos casos de tuberculose no Brasil 2003. Brasília: Brasil. Ministério da Saúde. Fundação Nacional de Saúde. Departamento de Vigilância Epidemiológica. Área técnica de Pneumologia Sanitária, 2004.
3. Robert J., Trystram D., Truffot-Pernot C., Jarlier V. Multidrug-resistant tuberculosis: eight years of surveillance in France. Eur Respir J 2003;22(5):833-7.
4. Yonemaru M., Toyoda T., Shirai T., et al. [Trends in drug-resistant tuberculosis in National Higashisaitama Hospital, 1994-2001]. Kekkaku 2003;78(2):83-7.
5. Bradford W.Z., Martin J.N., Reingold A.L., et al. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 1996;348(9032):928-31.
6. Koo D., Royce S., Rutherford G.W. Drug-resistant Mycobacterium tuberculosis in California, 1991 to 1992. West J Med 1995; 163(5):441-5.
7. Shafer R.W., Small P.M., Larkin C., et al. Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment. J Infect Dis 1995;171(1):170-6.
8. Salomon N., Perlman D.C., DePalo V.A., et al. Drug-resistant tuberculosis: factors associated with rise in resistance in an HIV-infected urban population. Mt Sinai J Med 1994;61(4):341-8.
9. Vanacore P., Koehler B., Carbonara S., et al.. Drug-resistant tuberculosis in HIV-infected persons: Italy 1999-2000. Infection 2004;32(6):328-32.
10. Drobniewski F., Balabanova Y., Nikolayevsky V., et al. Drug-resistant tuberculosis, clinical virulence, and the dominance of the Beijing strain family in Russia. JAMA 2005;293(22):2726-31.
11. Dewan P., Sosnovskaja A., Thomsen V., et al. High prevalence of drug-resistant tuberculosis, Republic of Lithuania, 2002. Int J Tuberc Lung Dis 2005;9(2):170-4.
12. Braga J.U., Barreto A.M., Hijjar M.A. Inquérito epidemiológico da resitência às drogas usadas no tratamento da tuberculose. Relatório final. Rio de Janeiro: Centro de Referência Professor Hélio Fraga/ FUNASA. Ministério, da Saúde, 1999.
13. Brito R.S., Gouder C., Lima D.B., et al. Drug-resistant Mycobacterium tuberculosis strains isolated at an AIDS reference center general hospital in Rio de Janeiro. J Bras Pneumol 2004;30:335-42.
14. Natal S., Valente J.G., Sánchez A.R., Penna M.L.. Isoniazid and rifampicin resistance and prior treatment for tuberculosis. Cad Saude Publica 2003;19 (5):1277-81.
15. Jardim P.C.R., Zamarioli L.A., Coelho A.G., et al. Resistência do Mycobacterium tuberculosis às drogas no município de Säo Vicente. Rev Inst Adolfo Lutz 2001;60(2):119-123.
16. Abrantes M.R. Perfil de resistência do Mycobacterium tuberculosis às drogas antituberculose em um serviço de referência em Natal-RN, 1997-1999. Instituto de Medicina Social. Rio de Janeiro: Universidade do Estado do Rio de Janeiro, 2000:55 p.
17. Gomes C., Rovaris D.B., Severino J.L., Gruner M.F. Perfil de resistência de M. tuberculosis isolados de pacientes portadores do HIV/AIDS atendidos em um hospital de referência. J Pneumol 2000;16(1):25-9.
18. Melo F.A.F., Afiune J.B., Ribeiro L.H.G., et al. Resistência primária do M. tuberculosis num serviço ambulatorial de referência em Säo Paulo: evoluçäo por três décadas e comparaçäo com outros estudos nacionais. J Pneumol 1996;22(2):3-8.
19. Silva E.A.M., Sato D.N., Telles M.A.S., et al. Perfil de resistência de Mycobacterium tuberculosis no Estado de Säo Paulo, 1986 a 1990. Rev Inst Adolfo Lutz 1992;52(1 /2):37-40.
20. Fandinho F., Kritski A., Hofer C., et al. Drug resistance patterns among hospitalized tuberculous patients in Rio de Janeiro, Brazil, 1993-1994. Mem Inst Oswaldo Cruz 1999;94(4):543-7.
21. Albuquerque M.F., Leitao C.C., Campelo A.R., et al. Prognostic factors for pulmonary tuberculosis outcome in Recife, Pernambuco, Brazil. Rev Panam Salud Publica 2001;9(6):368-74.
22. Castelo Filho A., Kritski A.L., Barreto A.W., et al. II Consenso Brasileiro de Tuberculose: Diretrizes Brasileiras para Tuberculose 2004. J Bras Pneumol 2004;30(supl 1):S2-S56.
23. Masur J., Monteiro M.G. Validation of the "CAGE" alcoholism screening test in a Brazilian psychiatric inpatient hospital setting. Braz J Med Biol Res 1983;16(3):215-8.
24. Manual de bacteriologia da tuberculose. Rio de Janeiro: Brasil. Ministério da Saúde. Centro de Referência Professor Hélio Fraga, 1994.
25. Canetti G., Grosset J.H. Techniques et indications des exames bacteriologiques en tuberculose. St. Mande, France: Edition de la Tourelle, 1968.
26. Barroso E.C., Rodrigues J.L.N., Pinheiro V.G.F., Campelo C.L. [Multidrug-resistant tuberculosis prevalence in Ceará State-Northeastern Brazil, 1990-1999]. J Pneumol 2001;27(6):310-4.
27. Höfling C.C., Pavan E.M., Giampaglia C.M., et al. Prevalence of katG Ser315 substitution and rpoB mutations in isoniazid-resistant Mycobacterium tuberculosis isolates from Brazil. Int J Tuberc Lung Dis 2005;9(1):87-93.
28. Dalcolmo M.P., Fortes A., Fiuza de Melo A.F., et al. Estudo de efetividade de esquemas alternativos para o tratamento da tuberculose multirresistente no Brasil. J Pneumol 1999;25:70-7.
29. Seiscento M., Melo F.A.F., Ide Neto J., et al. Multiresistant tuberculosis (MRTB): clinical, laboratorial, epidemiological, and therapeutic aspects]. J Pneumol 1997;23(5):237-44.
30. Telzak E.E., Chirgwin K.D., Nelson E.T., et al. Predictors for multidrug-resistant tuberculosis among HIV-infected patients and response to specific drug regimens. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG), National Institutes for Health. Int J Tuberc Lung Dis 1999;3(3):337-43.
31. Espinal M.A., Kim S.J., Suarez P.G., et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000;283(19):2537-45.
32. Mannheimer S.B., Sepkowitz K.A., Stoeckle M., et al. Risk factors and outcome of human immunodeficiency virus-infected patients with sporadic multidrug-resistant tuberculosis in New York City. Int J Tuberc Lung Dis 1997;1(4):319-25.
33. Pablos-Mendez A., Sterling T.R., Frieden T.R. The relationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996;276(15):1223-8.
34. Palmieri F., Pellicelli A.M., Girardi E., et al. Negative predictors of survival in HIV-infected patients with culture-confirmed pulmonary tuberculosis. Infection 1999;27(6):331-4.